Search
for
Sort by
Research 211–240 of 528
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Elevation of circulating DNAs of disease-associated cytokines in serum cell-free DNA from patients with alopecia areata
- Etiopathogenesis of Alopecia Areata
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- A review of Janus kinase inhibitor use in scarring alopecia
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Application of Baricitinib in Dermatology
- Janus kinase inhibitors for alopecia areata: A narrative review
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- JAK Inhibitors for Treatment of Alopecia Areata
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Hair Growth Effect of DN106212 in C57BL/6 Mouse and Its Network Pharmacological Mechanism of Action
- Microarray Gene Expression Analysis of Lesional Skin in Canine Pemphigus Foliaceus
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series